Psychosis Research Today is a free monthly online journal that collates and summarizes the latest research about Psychosis, including details on clinical depression, schizophrenia, bipolar disorder.

Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: benefits and risks.

Gladston S, Clarke DJ

Heath Lane Hospital, Heath Lane, West Bromwich, UK.

BACKGROUND: Clozapine is licensed for the treatment of psychotic illnesses resistant to other antipsychotic medications. Velo-cardio-facial syndrome (VCFS) is associated with a vulnerability to psychotic illness that may be resistant to treatment with conventional typical and atypical antipsychotics. PATIENTS AND METHODS: A 32-year-old man with intellectual disability (ID) and a long history of treatment-resistant psychosis was found to have VCFS. Treatment with typical antipsychotic drugs and with one atypical olanzapine produced no improvement. RESULTS: Treatment with clozapine produced an improvement in psychotic symptoms and associated behavioural abnormalities, but caused hypersalivation, constipation and a seizure disorder. The latter led to two fractures, one requiring surgery. The addition of sodium valproate stopped seizures. CONCLUSIONS: Clozapine may improve psychotic symptoms for people with ID associated with VCFS, but clinicians should be alert for potential adverse effects.

Published 21 June 2005 in J Intellect Disabil Res, 49: 567-70.
Full-text of this article is available online (may require subscription).

© 2005-2008 Psychosis Research Today. All Rights Reserved.